Joshua Maksi, MD
Neurology · Hattiesburg, MSNPI 1023123353
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,335 of the $28,159 with a category attached, or 65.1%. 53 manufacturers reported payments, led by AbbVie at 46.2% of the total. Reporting peaked in 2023 at $8,326 and has fallen 57.0% since, to $3,577 in 2025.
Across 1,040 payments — averaging $27.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$13K
- Acadia Pharmaceuticals Inc$1K
- SK Life Science, Inc.$903
- Pfizer$869
- AstraZeneca$844
- Eisai Inc.$818
- plus $10K from 47 others
What the payments were for
- Consulting fees$7,64227%
- Speaking & faculty fees$820%
- Travel & lodging$2,0917%
- Food & beverage$18,33565%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$9,698
How this compares
$28,159 in reported general payments places this provider in the 85th percentile of 111 neurology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 14 | $181,819 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $132,115 |
| IngrezzaValbenazine Tosylate | 11 | $81,503 |
| Nurtec OdtRimegepant Sulfate | 47 | $75,442 |
| Lamictal XrLamotrigine | 18 | $74,592 |
| QuliptaAtogepant | 46 | $58,873 |
| AptiomEslicarbazepine Acetate | 17 | $34,917 |
| UbrelvyUbrogepant | 21 | $29,780 |
| Aimovig AutoinjectorErenumab-Aooe | 24 | $24,378 |
| Emgality PenGalcanezumab-Gnlm | 21 | $16,935 |
| XcopriCenobamate | 11 | $12,205 |
| Levetiracetam | 397 | $9,677 |
| Oxcarbazepine | 138 | $9,163 |
| Carbamazepine ErCarbamazepine | 41 | $8,796 |
| Zembrace SymtouchSumatriptan Succinate | 11 | $8,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $23 | $181,81914 claims |
| Grifols USA, LLCGamunex-C | $206 | $132,11512 claims |
| AbbVieQulipta, Ubrelvy | $13,007 | $88,65367 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $308 | $81,50311 claims |
| PfizerNurtec Odt, Dilantin | $869 | $79,61768 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $488 | $34,91717 claims |
| SK Life Science, Inc.Xcopri | $903 | $12,20511 claims |
| Upsher-smith Laboratories LLCZembrace Symtouch, Topiramate | $143 | $11,052251 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $70 | $6,57856 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 111 neurology providers in Mississippi.
Other neurology in Hattiesburg
- Ronald SchwartzHattiesburg$352K
- Paula WarrenHattiesburg$114K
- Jose FernandezHattiesburg$20K
- Christopher LynnHattiesburg$20K
- Stephen LandyTupelo$1.9M
- Ruth FredericksJackson$943K
- Wendell HelvestonJackson$883K
- Rajesh SharmaJackson$152K
- Justin GraffTupelo$85K
- Patrick WeldonJackson$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.